Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANX1502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ANX1502 SAD | EXPERIMENTAL | Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo. |
| ANX1502 MAD | EXPERIMENTAL | Participants will be administrated multiple oral doses of ANX1502 at various ascending dose levels or matching placebo for 14 days. |
| Name | Type | Description |
|---|---|---|
| ANX1502 | DRUG | ANX1502 is a prodrug of ANX1439. |
| Placebo | DRUG | Placebo comparator. |
Key Inclusion Criteria: * Must be healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments (including supine blood pressure, supine pulse rate, respiration rate, and temporal body temperature), 12-lead electrocardiogram (ECG), and laborato...
ANX1502 is a small molecule C1 inhibitor being developed by Annexon, Inc. It is an investigational drug that has been studied in a Phase 1 clinical trial in healthy volunteers. Annexon trades on the Nasdaq under the ticker ANNX.
ANX1502 targets C1, a component of the complement system, and acts as a C1 inhibitor. By inhibiting C1, the drug is designed to modulate complement activity. The specific disease indications being pursued for ANX1502 have not been disclosed.
ANX1502 is being developed by Annexon, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker symbol ANNX. Annexon is the sponsor of the clinical program evaluating ANX1502.
ANX1502 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for the asset.
ANX1502 has been evaluated in one completed Phase 1 trial, NCT05521269, titled Dose Study of ANX1502 in Healthy Volunteers. The trial enrolled 135 participants in the Netherlands, was randomized, double-blind, and controlled, and included adults 18 years and older.